PHARMACY BENEFIT MANAGERS
-
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
The drugmaker also said late-stage results for a new drug for schizophrenia met its primary endpoints, helping to push its New York-listed shares up more than 13% to their highest level since 2019 in late morning trade. It is developing the monthly injection with France's Medincell.
-
Drugmaker AbbVie expects Humira volume erosion to worsen
-
Eli Lilly's nationwide insulin pricing settlement called off
-
Boehringer to lay off salespeople as Humira biosimilar sales lag
-
US FTC expands probe into pharmacy benefit managers
-
Insulin makers testify on Capitol Hill over prices
-
Abbvie raises sales outlook of two immunology drugs to more than $17.5 bln in 2025
Advertisement
Advertisement